Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21413070 | 0.81 | ALDH1A3 (0.38) | ALDH1A3ERN1TYRCYP1A2MAPT | |
| SCHEMBL1397054 | 0.81 | MEP1B (0.43) | TDP1ERN1TYRCYP1A2CYP2C9 | |
| SCHEMBL38651684 | 0.80 | ALDH1A3 (0.37) | ALDH1A3ERN1TYRCYP1A2MAPT | |
| SCHEMBL18502977 | 0.80 | L3MBTL1 (0.36) | MAPT | |
| SCHEMBL18508480 | 0.80 | L3MBTL1 (0.36) | MAPT | |
| SCHEMBL18489109 | 0.77 | ALDH1A1 (0.38) | TDP1ERN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1253375 | 0.76 | CA1 (0.43) | ALDH1A3TDP1ERN1CYP1A2MAPT | |
| SCHEMBL14920787 | 0.75 | ALDH1A1 (0.36) | TDP1ERN1MAPTMEP1B | |
| SCHEMBL29952801 | 0.75 | — | — | |
| SCHEMBL15912973 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428062-B2 | Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-10-01 | — | — | US | disclosed |
| US-10428062-B2 | Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-10-01 | — | — | US | disclosed |
| EP-3334740-A1 | GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF 7-NICOTINIC ACETYLCHOLINE RECEPTORS | Axovant Sciences GmbH (DE) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017027600-A1 | GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20170044155-A1 | Geminal Substituted Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | AXOVANT SCIENCES GMBH (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20170044155-A1 | Geminal Substituted Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | AXOVANT SCIENCES GMBH (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20170044155-A1 | Geminal Substituted Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | AXOVANT SCIENCES GMBH (CH) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044155-A1 | Geminal Substituted Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | CHRNA7, CHRNA5, CHRNA6 | ALDH1A3 3562/4885TDP1 2381/4885ERN1 4726/4885 |
| US-10428062-B2 | Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA2 | ALDH1A3 3608/4885TDP1 2421/4885ERN1 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.